Background: Pax-5 belongs to the Pax gene family transcription factors that play an important role in organogenesis and in B cell ontogeny. It is expressed in B cell non-Hodgkin’s lymphoma (B-NHL), Hodgkin’s lymphoma (HL) and neuroendocrine carcinomas. However, its expression in other tumour types is not fully explored.
Aims and methods: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections.
Results: Pax-5 was expressed in 108/118 (91.5%) B-NHLs, in 60/70 (85.7%) HLs and in 0/7 T cell lymphomas. In addition, Pax-5 was seen in 24/34 (70.6%) Merkel cell carcinomas, 42/53 (79.2%) small cell carcinomas, 1/164 (0.6%) breast carcinomas, 2/204 (1%) endometrial adenocarcinomas and 1/452 (0.2%) urothelial carcinoma of the bladder.
Conclusion: Despite its expression in a small subset of malignancies of epithelial origin, Pax-5 is still a good and reliable immunomarker in diagnosing B-NHL, HL and neuroendocrine carcinomas.
- HL, Hodgkin’s lymphoma
- IHC, immunohistochemistry
- MCC, Merkel cell carcinoma
- NHL, non-Hodgkin’s lymphoma
- PAX, pair box
- RT, reverse transcriptase
- SCC, small cell carcinoma
- UC, urothelial carcinoma
Statistics from Altmetric.com
Published Online First 12 July 2006
Competing interests: None declared.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.